• Cancer screenings, treatments declined during COVID-19 pandemic, highlighting need for personalized therapies to improve outcomes
• Comprehensive genomic, transcriptomic sequencing of patient samples complete, patient outcome data obtained from UPMC-Magee
• Project is template for future partnerships with other healthcare institutions to expand POAI’s AI-driven clinical models to other cancers

The consequences of COVID-19 sent shock waves throughout the healthcare sector in more ways than just the direct impact of coronavirus infections. A recent study (https://ibn.fm/6LLiW) showed that cancer screenings and treatments declined during the pandemic, with the authors cautioning that the fallout could be dramatic. The study’s results certainly highlight the need for more individualized treatment regimens that improve patient outcomes, minimize patient visits and help patients with advanced disease at the time of treatment. This is the area of specialty of Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery. Through its Helomics division, the Minneapolis-based company has just made a significant stride in its efforts to build AI-driven models of ovarian cancer by completing key data generation milestones in a retrospective study in collaboration with UPMC-Magee Women Hospital, an affiliate of the University of Pittsburgh Schools of the Health Sciences (https://ibn.fm/KSr2G).

While the science and technology are complex, the overarching concept isn’t: Test drugs on individual tumors in a lab setting to better inform doctors’ decisions in the real world. Effectively, Helomics performs chemotherapy on a patient’s tumor before the patient gets the drug to provide the oncologist with information on what may or may not work before the oncologist ultimately prescribes a treatment plan.

During more than 15 years of clinical testing, Helomics has amassed a proprietary knowledge base, coined TumorSpace(TM), of more than 150,000 tumor drug response profiles. Simply, Helomics grows patient tumors and tests how they respond to drugs, constantly analyzing and collating data as it builds multi-omic predictive models of tumor drug response and outcome. “Multi-omic”—biotech speak for integrating data collected from different omic levels (meaning things like genomes, proteome, etc.) to understand interactions and influence on disease pathogenesis—involves using cutting-edge machine learning technology to combine a drug response profile with a genomic profile to deliver a more meaningful and effective impact than genomics alone could.

Helomics currently provides treatment option recommendations to personalize therapy based on tumor profiles as it continues development of its AI-driven models. Once the AI models are complete and validated, it will move exclusively to the AI-driven computer models.

As it happens, looking back is often the best way to move forward. That was the purpose of the study with UPMC-Magee Women Hospital. Comprehensive genomic and transcriptomic sequencing of patient samples is now complete, and patient outcome data has been obtained from UPMC-Magee. These data will now be used to drive POAI’s AI models of ovarian cancer and their internal ovarian cancer drug re-purposing project.

“The successful generation of high-quality genomic and transcriptomic data from archived materials at Helomics, together with the gathering of historical outcome data from our collaborator UPMC-Magee, demonstrates that we can leverage Helomics’ unique asset and deliver significant value,” said Predictive Oncology CEO Dr. Carl Schwartz. “Furthermore, this project is a template we can use to partner with other healthcare institutions and expand our AI-driven clinical models to other cancers.”

According to the American Cancer Society, about 21,410 women will receive a new diagnosis of ovarian cancer this year and approximately 13,770 women will die from the disease.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Cybin’s latest offering generated exceptional demand; announces upsize of “bought deal” offering
• Burgeoning psychedelic sector attracts investors’ attention as compound may prove effective in mental health treatments.
• Cybin appears set for rapid growth as research accelerates, public acceptance grows.

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotech company focused on psychedelic therapeutics for various psychiatric and neurological conditions, has announced that it has upsized the terms of its “bought deal” offering due to strong demand. The deal size, previously announced at CDN$20,025,000, has increased to aggregate gross proceeds of CDN$30,015,000 as the underwriters have agreed to purchase 13,340,000 units of the company at CDN$2.25 per unit. Cybin intends to use the net proceeds to further develop its clinical trials, novel molecule programs and technologies enhancing the patient experience as well as for working capital and general corporate purposes.

The announced upsize comes against the backdrop of a growing demand for psychedelic companies. The burgeoning sector is attracting increasing attention from investors with more companies going public and rapidly increased research sparking greater public acceptance and potential decriminalization (https://ibn.fm/RS6Y1). The stigma around the compound has started to wane as recent studies point towards the potential use of psilocybin, which is found in “magic” mushrooms, for treating patients suffering from mental health diseases such as depression, anxiety and PTSD.

More and more academic institutions, including those with a world-class reputation such as Johns Hopkins and Imperial College London, are establishing specialized programs to further investigate the role psilocybin could play in the mental health space, especially in alleviating symptoms of major depression. In the past, criminalization and the stigma attached to the compound have hindered researchers from exploring the medical benefits of psilocybin and other psychedelics. More recently, however, the push to remove the barriers to research has been gaining momentum.

Cybin is committed to developing novel therapeutics, delivery methods and treatment regimens based on psychedelic compounds such as psilocybin, DMT, MDMA and other analogues to potentially treat neurological disorders. The company is working to become the first company to bring a psilocybin drug to market targeting major depressive disorder addressing a vast potential market with an estimated 17 million people in the United States and 300 million people worldwide experience depression (https://ibn.fm/Tn0bb). As a company developing psychedelic therapeutics for psychiatric and neurological conditions and with a strong executive medical and research team that boasts extensive experience in the field, Cybin appears well-positioned within the thriving sector that is set for rapid growth as research accelerates and public acceptance grows.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Nextech AR Solutions Corp. is a leading provider of web-based augmented reality for e-commerce, advertising and virtual events
• The company provides businesses with a powerful end-to-end augmented reality platform designed specifically to increase online sales
• Nextech AR’s current customer base includes the likes of Amazon, Johnson & Johnson, ViacomCBS, Toyota and Carnegie Mellon University
• The company achieved record bookings in Q4 2020 of $7.3 million (estimated), marking a greater than 275% year-over-year increase
• The Nextech AR management team has extensive experience stemming from time with a collection of Fortune 500 companies

Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF), based in Vancouver, Canada, is a leading provider of web-based augmented reality for e-commerce, advertising and virtual events, with technology ranging from simple 3D images to using 360-degree videos. Nextech AR provides businesses with a powerful end-to-end augmented reality platform designed specifically to increase online sales. The company is currently pursuing four unique verticals with its innovative technology, including:

• Virtual Conference Platform: Nextech’s advanced Augmented Reality and Video Learning Experience Platform for Events leverages an SaaS model to give organizations the ability to create engaging virtual event management and learning experiences. Automated closed captions and translations for over 64 languages are available. The global virtual events market was valued at $90 billion in 2020 by Grandview Research, and it’s expected to reach more than $400 billion by 2027.
• ARitize(TM) for eCommerce: Launched in early 2019, the company’s SaaS platform for webAR in eCommerce serves as a ‘full funnel’ end-to-end e-commerce solution for the AR industry. The solution includes the Aritize360 app for 3D product capture, ‘Try it On’ technology for online apparel, 3D and 360-degree product views, ‘one click buy’ and much more.
• ARitize(TM) 3D/AR Advertising Platform: Launched in Q1 2020, this ad platform is being marketed as the industry’s first end-to-end solution leveraging 3D asset creation for 3D/AR ads. In 2019, according to IDC, global advertising spend totaled roughly $725 billion.
• ARitize(TM) Hollywood Studios: The studio is in development as a means of producing immersive content using 360-degree videos and augmented reality as primary display platforms.

Unique Marketing Strategy Nextech AR’s efforts to disrupt the market for web-based augmented reality for e-commerce are supported by a unique go to market strategy. First, the company seeks to build or acquire platforms targeting a number of rapid growth industries, most notably AR, edTech, e-commerce, 3D/AR advertising and virtual & hybrid events. After identifying these market opportunities, the company seeks to integrate new AR technologies into existing or novel platforms in an effort to secure market share and promote growth. These technologies include WebAR, Human Holograms, 360 Portals, ScreenAR, Genie in the bottle and AiRShow. Nextech AR then aims to leverage these platforms to land and expand partnerships with a number of blue chip customers. The company’s current customer base includes the likes of Amazon, Johnson & Johnson, ViacomCBS, Toyota and Carnegie Mellon University. Growth Capital Nextech AR generates revenue through a software-as-a-service model from technology services, delivery of service revenue and sales of products through e-commerce. As noted in its latest investor presentation, the company achieved record bookings in Q4 2020 of $7.3 million (estimated), marking a greater than 275% year-over-year increase. The company also realized greater than 235% revenue growth for calendar 2020, reporting $20 million for the 12-month period. Nextech AR attributes its 2020 increase in revenues to the contracts secured with new customers, expanded agreements with existing customers and additional conversions from e-commerce channels. With its newly launched 3D ad network now bolstering its operations, Nextech AR is projecting revenues in excess of $50 million for 2021. Recent Company Highlights

• February 16, 2021: The company announced it has hired Zak Mcleod, formerly of Fastly, as its new Senior Director of Sales – EMEA. The company also announced that Rory Ganness, formerly of Salesforce.com, has joined the Nextech team as Director of Enterprise Sales – North America.
• February 11, 2021: The company announced the launch of version 2.0 of its AiR Show app, an application that turns top music artists into interactive ‘live’ holograms, providing an immersive and engaging AR experience.
• February 8, 2021: The company announced the launch of new standardized chat features within its Virtual Experience Platform (“VXP”) and recently-launched ARoom collaborative streaming solution. Nextech will also offer the chat platform as a stand-alone SaaS service externally, increasing the company’s revenue potential for 2021.
• January 26, 2021: The company announced, in partnership with ARB Meetings and Events, it has signed a six-figure annual contract to supply its InfernoAR video conferencing and virtual events platform to NAMD.
• January 25, 2021: The company announced that Strategic Site Selection (“SSS”), a 15 year old site selection leader in the meeting and events industry, has selected Nextech AR as a preferred channel partner, making Nextech’s industry leading virtual experience platform and services available to SSS clients.
• January 20, 2021: The company announced that Microsoft’s Azure Cloud Services platform will be a standard offering across its virtual experience platforms and consumer apps, enabling hyper-scalable, secure and immersive events and applications for users.
• January 15, 2021: The company signed a renewal agreement with Poly with an initial value of $470,000 for a six-month term and the potential for additional revenue after the six months.

Management Team Evan Gappelberg is CEO and Founder of Nextech AR. He is an experienced operating executive specializing in creating, funding and running hyper-growth startups in both the public and private sectors. Notably, he took Take-Two Interactive Software Inc. (NASDAQ: TTWO) public with a market cap of $30 million and played a key role in guiding its growth to a current market cap of roughly $14 billion. Mr. Gappelberg has extensive experience as both a hands-on operating executive and a public markets professional. Paul Duffy is the company’s President. He is a serial entrepreneur with over 25 years of experience in successfully starting, expanding, diversifying and selling global technology companies. Mr. Duffy is the creator of the HumaGram and inventor of the patent for Holographic Telepresence over the Internet (“TOIP”). Augen Winschel is the COO of Nextech AR. He is an 18-year SAP executive with over 20 years of leadership experience in the areas of business management, business operations, marketing, product management, digital business and enterprise artificial intelligence. Kashif Malik, CPA, CA, is the company’s CFO. He has over 15 years of financial experience spanning IPOs, M&A activity, corporate restructuring and capital raising. Mr. Malik has worked globally with public and private companies, including Merck & Company Inc. (NYSE: MRK), Real Matters Inc. (TSX: REAL) and Constellation Software Inc. (TSX: CSU). He obtained his Chartered Accountant designation while working at Deloitte. Hareesh Acchi is the company’s President of 3D/AR Advertising. He is a 20-year Microsoft technology veteran with experience leading digital transformation and scaling businesses and enterprise organizations across the advertising industry. For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF

• Massive opportunity ahead says CEO of Autonomous Security Robot maker Knightscope
• Wide ranging interview discloses vast potential in federal applications
• Knightscope’s state of the art ASRs provide cost effective 24/7/365 security

The rise of machines has arrived. Relax, it isn’t the rise of Skynet, the malevolent neural network superintelligence system from the movie Terminator. This rise of machines has no malice. In fact, these machines benefit society by uniquely combining robotics, self-driving technology, and artificial intelligence to reduce crime as well as provide safety, security, and real-time data in a multitude of settings. With the rise of its Autonomous Security Robots (“ASRs”), tech innovator Knightscope is on track to revolutionize the $500 billion security industry. The company is rapidly displacing moribund security duties across the country and its ASRs are already on-guard in federal government facilities, public institutions, and numerous Fortune 1000 companies. Knightscope’s ASRs operate 24/7/365 providing real-time access to data around the clock and can capture 90 terabytes of data each year. These machines also feature 360-degree eye-level HD video streaming, people detection, facial recognition, automatic license plate recognition, thermal anomaly detection, and automatic signal detection. Not only does the presence of ASRs help deter crime, but these sentries also help law enforcement reaction times, provide resolution to any legal matters with recorded video as well as provide training and operational improvement opportunities. On top of all the technological wizardry, Knightscope’s ASRs save customers money by cost effectively augmenting the high costs of security. The future looks bright for Knightscope. In a recent IPO Edge Fireside Chat with Knightscope CEO William Santana Li was quite bullish on the outlook. He sees a massive opportunity ahead, especially with the federal government. In the interview he stated, “The federal government is going to be, I think, a long term very very large client for us.” As Mr. Li outlined, just think of all the federal applications that need augmented 24/7/365 security. Military bases and their storage facilities, national parks, FEMA warehouses, Federal courthouses – the list of applications is seemingly endless, and the company is on a roll. Knightscope has brought the future to the present with its innovation and market disrupting technology. The company is rapidly gaining traction, deploying its sentries to public and private entities, saving customers money, and providing improved security across the country. There’s certainly nothing to fear from this rise of machines. For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Ideanomics, Inc. (NASDAQ: IDEX) recently entered into an investment agreement promising to purchase over 6 million Energica ordinary shares using a subscribed-shares arrangement that priced each subscribed share at Euro 1.78
• In total, IDEX would invest approximately 13 million dollars in the Italy-based manufacturer of all-electric high-performance motorcycles
• According to IDEX CEO Alf Poor, the investment was driven by Energica’s manufacture of high-performance products that produce zero emissions
• In 2020, Energica experienced a 187% increase in revenue compared to 2019, and there is high demand for Energica’s motorcycles in the U.S.

Ideanomics (NASDAQ: IDEX), a global company focused on investing in and promoting innovative solutions in the financial and electric vehicle (“E.V.”) spaces, recently entered into an investment agreement with Energica Motor Company S.p.A. (“Energica”), an Italian listed electric motorcycle company, that will see it acquire at least 20% of Energica, upon completion of the requisite transactions. According to a March 4 announcement issued by Energica, IDEX promised to purchase 64% of the share capital increase, the equivalent of 6,128,703 Energica ordinary shares, in a subscribed-shares arrangement. Notably, subscribed shares are shares that investors promise to buy as part of an initial public offering or a share capital increase (https://ibn.fm/H10Ca). Under the agreement, IDEX would pay a subscription price of Euro 1.78 per share, arrived at by calculating the weighted average of the official price of Energica shares over the six months prior to the execution of the transaction, bringing IDEX’s total subscribed share capital to Euro 10,909,091. The transaction would be settled in the few days following the publication of the announcement. Once completed, the transaction will bring the total number of Ideanomics’ wholly-owned businesses and companies wherein it is a direct investor in the EV space to 7 (https://ibn.fm/TzfpG). The latest investment, Energica, will be part of Ideanomics’ Mobility division and is the second of its kind for IDEX, which acquired a controlling stake in Treeletrik’s sales and distribution arm in March 2019. At the time, Treeletrik, which manufactures all-electric bikes, was the only licensed EV manufacturer in Malaysia. Therefore, the investment in Energica looks like a calculated strategy in Ideanomics’ quest for a wholesome portfolio that includes every category of E.V.s, namely buses, vans, cars, trucks, and motorcycles, also allowing battery technology synergies to play out between Energica and Treeletik Energica, the first Italian manufacturer of high-performance electric motorcycles, has posted growth in its revenue and order backlog year-on-year. According to its preliminary 2020 turnover report, the manufacturer posted Euro 6 million in revenue, constituting a 187% increase from the figure reported at a similar period in 2019 (https://ibn.fm/ARZNJ), despite the vagaries brought by the pandemic. “Energica has combined zero emission E.V. technology with the pedigree of high-performance mobility synonymous with Italy’s Motor Valley to create a range of exceptional products for the high-performance motorcycle market,” Alf Poor, CEO of Ideanomics, said of the company. “We were very impressed with Livia (Energica’s CEO) and her team throughout our discussion, and we are very pleased to support them through their next phase of growth.” In the first two months of the 2021 fiscal year – starting December 2020 – Energica had already received new orders valued at over Euro 2.9 million and equivalent to 49.7% of the orders it received throughout 2020. 30% of these orders were from the United States. Moreover, the U.S. orders received between March 25 and April 28 accounted for 41% of the total. These figures signal that Ideanomics’ investment in the motorcycle manufacturer could also be due to the increasing popularity of Energica’s motorcycles in the North American market. On her part, Livia Cevolini voiced her pride in being part of a unified platform that shared the same vision. “The creation of a network of innovative companies can only accelerate the growth and adoption of new technologies such as sustainable mobility that sees us among the leaders,” she continued. “The investment will give further strength to the Energica growth already underway in recent years thanks to the innovation brought to our products with the racing experience in MotoE.” The investment brings Ideanomics closer to realizing its vision to build advanced technology ecosystems that deliver more efficient and environmentally-friendly solutions to the world. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• Canada House subsidiary Abba Medix to distribute Pure Extract line of full spectrum oil vape and edible products throughout its nationwide network
• Partnership widens Pure Extracts’ footprint in Canada’s growing Cannabis 2.0 market
• Global extraction product market expected to reach $28.5 billion in next six years
• New agreement strengthens Pure Extracts’ sales channels as it looks towards international expansion

There’s plenty of media coverage about increasing legalization of cannabis for medical and adult recreational use driving a broad market expected to reach $73.6 billion by 2027 (https://ibn.fm/ICOlM), but not as much about the cannabis extraction market that is growing at nearly the same annual clip (18.1% vs. 16.6%, respectively) to reach $28.5 billion at the same time (https://ibn.fm/jPkyu). Perhaps it is because people can easily grasp the top-level idea of smoking cannabis buds, while the idea of processing cannabis and hemp into tinctures, oils, vapes, edibles and other products like Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) does is far more complex. It’s arguable, though, that buds, excluding high-end crafts and medical grade, are a bit of a race to the bottom with pricing while extraction products seem sexier with their diversity of applications and higher margins.

The onset of Cannabis 2.0, the colloquial name for regulatory changes late in 2019 that legalized marijuana derivative products in Canada, paved the way for a spate of new products to hit retailer shelves in 2020, but the momentum has been a slow build that is now accelerating. Data from Statistics Canada shows that 527,987 units of adult-use extract products were bought in Canada in January 2020, a figure that swelled to 1.33 million units in October 2020 (https://ibn.fm/OrgQL). Increased awareness as to the bevy of benefits of cannabis compounds amongst consumers and patients is expected to drive market growth going forward, according Data Bridge Market Research, which predicts a 21.0% CAGR to 2027 for the extract market (https://ibn.fm/EDfDt).

As consumer uptake grows, Pure Extracts is positioning to widen its Canadian footprint for its lineup of Cannabis 2.0 products. On Friday, the Vancouver-based company said it partnered with integrated medical cannabis company Canada House Wellness Group (CSE: CHV). Per the pact, Canada House’s Abba Medix Corp. unit will distribute Pure Extracts’ line of concentrate products through its established provincial distribution channels.

Pure Extracts CEO Ben Nikolaevsky sees the new partnership as a quick and efficient way to get the Company’s line of full spectrum oil vape and edible products to retail buyers across Canada while their Sales Amendment application is being processed by Health Canada.

“We’ve been extremely impressed with the Pure Extracts team and the brand presence they have established, particularly in the western provinces, and are looking forward to supporting their commercialization efforts in a mutually beneficial way,” commented Canada House CEO Chris Churchill (https://ibn.fm/WHVZC).

Pure Extracts operates a 10,000 square foot state-of-the-art processing facility situated 20 minutes north of Whistler, British Columbia. The new facility was purpose built to European GMP (good manufacturing practices) standards as Pure Extracts looks ahead towards export sales of products and formulations, which include not only cannabis, but hemp biomass, and functional and psychedelic mushroom products as well.

Already possessing a Standard Processing License by Health Canada under the Cannabis Act, Pure Extracts is aligning for additional licenses and certifications that will facilitate exporting a diverse product line. These are expected to include even products restricted in Canada at this time, but legally available in countries internationally.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Imagin Medical has developed a technology, currently entering the manufacturing stage, which it believes will revolutionize bladder cancer surgical imaging
• The company’s technology, the i/Blue Imaging System, can display blue and white light images of the bladder side-by-side simultaneously, allowing surgeons greater ability to detect and remove tumors
• Imagin has raised a $2.165 million convertible note offering to fund the company during the manufacturing phase of its surgical imaging system as well as the U.S. Food and Drug Administration (“FDA”) approval process
• Bladder cancer is one of the most prevalent cancers in the United States, particularly in men, and is expected to result in the deaths of roughly 17,200 patients this year — approximately 71 percent of them men

The American Cancer Society forecasts that in 2021 about 83,730 new cases of bladder cancer will be diagnosed in the United States, about 77 percent of them in men. And that about 17,200 bladder cancer cases will result in death, about 71 percent of them in men (https://ibn.fm/6NEqE). While bladder cancer rates have been declining for the past decade, the ACS predicts there will be a 3 percent increase this year (https://ibn.fm/8KYwX).

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is preparing to commercialize its proprietary i/Blue Imaging(TM) System once final U.S. Food and Drug Administration (“FDA”) approval has been granted. The purpose-built mission of the i/Blue Imaging System is to bring about a marked improvement in bladder cancer detection through cystoscopy (using conventional endoscopes inside the body to help surgeons detect and resect tumors) and thereby help reduce the incidence of recurrence or severe progression of such cancers.

While cystoscopy has wide use in resecting bladder cancers, it has largely relied on normal visual range white light for illuminating the bladder on surgeons’ video screens despite technological advances by industry suppliers and researchers who have determined blue light and a pink staining dye can help surgeons more effectively locate tumors for resection and remove them more completely.

“Here is the crux of the problem urology has long faced: cystoscopy is the standard of care for diagnosing bladder cancer, but cystoscopy relied upon incident white light from the instrument. White light misses 50% of malignant bladder lesions,” a physician who serves as editor-in-chief of investment media outlet BioPub states in a recent opinion article that touts Imagin’s efforts (https://ibn.fm/okNai). “‘Houston we have a problem:’ when your standard of care is that compromised, you can see how bladder cancer would cultivate a reputation for being hard to cure. Imagin, a small Canadian biotech, has been working behind the scenes with genuine thought leaders in urology to improve diagnostic yield at cystoscopy, and now seems to have done so.”

Imagin is a company “where, when you think about the methodology they’re promulgating, you’re like, it’s so obvious in retrospect,” the physician, known as Dr. KSS, says in an episode of his webcast (https://ibn.fm/3h9Q0). “How did it take medicine so many decades to get to this point? … (The i/Blue Imaging System) is a system that we think will become state of the art, that operators will be really impelled to install lest they not be with standard of care.”

A report by Urology Times described cost benefits from using blue light cystoscopy procedures, stating that in the initial transurethral resection of bladder tumors the procedures “lowered costs by $4,660 over 5 years compared with use of white light cystoscopy alone” and led to a lower overall burden for patients (https://ibn.fm/COXAr).

One reason Imagin cites for blue light cystoscopy being underutilized is that surgical centers already have an inventory of conventional endoscopes that use white light. Current blue light technology requires the purchase of new customized endoscopes that are only available from one manufacturer, not only adding cost but also rendering the current inventory useless.  In addition, blue light cystoscopy still requires white light images in order to operate, so surgeons need to switch back and forth between the white and blue light images during the procedure to get the full picture of the cancer in the bladder.

Imagin’s i/Blue Imaging System advances existing technologies by using a dualview camera technology that controls images on the monitor and that can be adapted to almost any existing endoscopic equipment surgical centers already own. The i/Blue system can display both blue light images and white light images side-by-side simultaneously during the procedure, eliminating the challenges of comparing blue and white light images by toggling back and forth.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Head CTs, MRIs are most-used but not most-effective tool for head trauma or neurological issues in triage
• EEG changed clinical management of 76.2% of patients, even when CT or MRI was available
• Brain Scientific has overcome key barriers causing EEG underuse in emergency medicine

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company, is making EEGs accessible in emergency departments (“ED”) with cutting-edge tech that bridges the widening gap in access to quality care. As the public becomes more aware of head trauma’s long-term effects, triages fill up with potential TBIs and acute neurological conditions. Facilities are scrambling to adapt to the growing need but are often ill equipped to do so.

When a patient arrives presenting head trauma or neurological issues, almost reflexively, a head CT and/or MRI is ordered. A BRSF white paper titled “Electroencephalography in the Emergency Department” explains why this is not always the most effective diagnostic tool (https://ibn.fm/IWTxt).

The report notes that head CT is not always the optimal scan for all acute neurological conditions; however, due to its availability, it is overused. Around 70 million CT examinations are performed in EDs annually in the United States (https://ibn.fm/gwcGo). While these are ideal for brain hemorrhage, skull fractures, malignancy and a handful of other conditions, they have been found ineffective at identifying mild traumatic brain injury (“mTBI”) and nontraumatic causes of neurologic dysfunction such as syncope, delirium, and vertigo. The MRI provides higher resolution images and greater detail of the brain than the CT but is limited as a primary diagnostic tool in the ED.

According to the CDC, an estimated 2.5 million TBI-related visits are made to the ED in the U.S. a year (https://ibn.fm/cppKg). Part of the increase is due to the public’s growing knowledge of TBI effects. Neither the head CT or MRI are equipped to diagnose mTBI adequately. The best indicator is an EEG, which can determine the severity of the injury.

Delirium is also often seen in the ED and can affect up to one-half of older patients in hospitals. However, experiencing delirium in a hospital setting does not mean a patient has Alzheimer’s or another dementia diagnosis. Dementia is chronic, while delirium is usually reversible. Determining what the patient is experiencing is essential in creating a successful care plan. An EEG can make this distinction.

The American Academy of Neurology published a study on routine EEGs in emergency room and inpatient services. It was found that the use of the EEG changed the clinical management of 76.2% of patients, even when a normal CT or MRI was available (https://ibn.fm/gCNV4).

Beyond TBIs and dementia, EEGs are also used to diagnose epilepsy and other acute neurological conditions that CTs and MRIs are simply not designed to find.

So why are EEGs not used more often?

The size of traditional EEG systems, lack of portability and inadequate numbers of trained EEG personnel are key factors contributing to the underuse of the EEG in emergency medicine. Utilizing equipment that takes hours is not feasible in a triage situation. Brain Scientific has overcome these barriers with two separate devices: the NeuroCap(TM) and NeuroEEG(TM). Low cost, portable, small, wireless, and easy to set up, these devices make it possible for EEGs to be utilized in emergency departments across the country.

To learn more about this company, visit www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• POAI completes two separate fundraising initiatives: private placement, direct offering.
• Two fundraising campaigns expected to result in $17.6 million, $7.4 million respectively.
• Predictive Oncology plans to use funds to pay off debt as well as for working capital, general corporate purposes.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced two funding initiatives that together total an estimated $25 million. The company has entered into securities purchase agreements with institutional and accredited investors (https://ibn.fm/WH4nw) to raise approximately $17.6 million and is involved in a direct offering that is expected to raise $7.4 million (https://ibn.fm/uSv23).

The securities purchase agreement was comprised of a total of 9,043,766 shares of common stock and warrants, offered at a purchase price of $1.95 per share. The private placement was expected to close around Feb. 22, 2021. In the announcement of the private placement, Predictive Oncology noted that it planned to use some $5.88 million of the net proceeds from the placement to pay off debt; the company has earmarked the remaining funds for general corporate purposes.

The direct offering is also between POAI and select institutional and accredited investors. Consisting of approximately 4,222,288 shares of common stock offered at a purchase price of $1.75 per share, the offering was expected to close approximately Feb. 26, 2021. The company noted that it plans to use the $7.4 million net proceeds from this placement for working capital purposes.

In the past, the pharmaceutical industry has invested heavily in genomics and big data, hoping to better understand individual patient’s genomes and deliver targeted therapeutics. In reality, the use of genomics alone has proven to be disappointing. Predictive Oncology is confident that a multi-omic approach offers much greater chance of success. Unfortunately, few comprehensive, multi-omic datasets exist, and such data is difficult to access quickly as it is both costly and time consuming to initiate prospective data collection – especially in cancer, an area where Predictive Oncology is focused.

POAI, however, is a leader in the nascent multi-omic game. The company has spent years gathering an estimated 150,000 clinically validated cases on its molecular information platform, with more than 38,000 of those specific to ovarian cancer. The data in POAI’s molecular information platform are highly differentiated, having both drug response data and access to historical outcome data from those patient samples. Predictive Oncology is focused on generating additional sequence data from these tumor samples to deliver on the unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development and, most importantly, improved patient outcomes. The recently acquired funds will go far in assuring the progress of this work.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Increased nuclear power projects fueling rising demand for uranium
• UEC controls one of the largest historical uranium exploration and development databases in United States
• UEC property portfolio includes properties previously explored and developed by senior energy firms
• UEC has fully licensed, low cost, ISR projects positioned to supply the U.S. Uranium Reserve
• Nuclear energy included in Democratic Party’s energy platform for first time in 48 years

After spending a solid ten years in a downward trend, uranium stocks are now making fresh 52-week highs amid increased demand for energy (https://ibn.fm/GXF7e). Uranium Energy (NYSE American: UEC), a U.S.-based uranium mining and exploration company that controls one of the largest historical uranium exploration and development databases in the United States, is positioned to benefit from the trend after having acquired multiple mining sites in North and South America that allow the company to target specific uranium-rich areas.

Increased global demand for nuclear energy continues to drive the demand for uranium while long-term supplies are becoming less certain. Analyst Lyn Alden Schwartzer of Seeking Alpha predicts robust and increasing demand for uranium from developing nations and manufacturing powerhouses like China that continue to increase nuclear power consumption (https://ibn.fm/EI3BY). With lead times for new production spanning between seven to ten years or longer, current prices are not yet at levels that incentivize future production, further exacerbating longer-term supply concerns. Despite these conditions, uranium’s spot price is currently less than its production cost for most Western producers, signaling potential opportunities for suppliers and investors.

UEC controls one of the largest historical uranium exploration and development databases in the United States with properties in various locations, including Texas, New Mexico, Colorado, Arizona and Wyoming. The company’s use of historical exploration data has enabled it to target and acquire properties that have already been explored and developed by senior energy firms in the past, in some cases spending as much as $50 million to develop individual projects.

Since inception in 2005, UEC’s main strategic focus has been on acquiring and developing U.S. in-situ recovery (“ISR”) projects that are an environmentally friendly and lower-cost alternative to conventional mining. The Company has a near-term extraction profile of 4 million pounds of U3O8 per year from its south Texas and Wyoming ISR projects.

Long-term fundamentals underlying the uranium market continue to strengthen. Projections from industry analysts reveal annual deficits between production and utility requirements of about 40 million pounds well into 2026, with the gap approaching almost 70 million pounds per year by 2030.

With its fully licensed, low-cost U.S. ISR projects, UEC is also very well positioned to participate in the United States strategic uranium reserve. The uranium reserve budget is $1.5 billion over ten years for domestic uranium and conversion, with initial funding of $75 million approved by Congress for fiscal 2021. While predicted demand for uranium plays strongly into analysts’ forecasts, optimism is further bolstered by bipartisan support for nuclear energy that includes its inclusion into the Democratic Party’s energy platform for the first time in 48 years.

Uranium Energy Corp is a U.S.-based uranium mining and exploration company. In South Texas, the Company’s hub-and-spoke operations are anchored by the fully-licensed Hobson Processing Facility, which is central to the Palangana, Burke Hollow and Goliad ISR projects. In Wyoming, UEC controls the Reno Creek project, which is the largest permitted, pre-construction ISR uranium project in the U.S. Additionally, the Company controls a pipeline of uranium projects in Arizona, New Mexico and Paraguay, a uranium/vanadium project in Colorado and a large, high-grade ferro-titanium project in Paraguay. The Company’s operations are managed by professionals with a recognized profile for excellence in their industry, a profile based on many decades of hands-on experience in the key facets of uranium exploration, development and mining.

For more information on Uranium Energy Corp., visit the company’s website at www.UraniumEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to UEC are available in the company’s newsroom at https://ibn.fm/UEC